Studies involving Diversity Outbred (J:DO) population      

Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Attie2 biomarker quantification
with high-fat high-sucrose diet 		Bile acids in feces. DO population both 4-26wks 2018
Attie2 body weight
with high-fat high-sucrose diet 		Weekly. DO population both 4-26wks 2018
Attie2 colony observation
with high-fat high-sucrose diet 		Number of days on high-fat high-sucrose diet. DO population both 4-26wks 2018
Attie2 DXA
with high-fat high-sucrose diet 		Bone mineral density. Isolated tibia. DO population both 4-26wks 2018
Attie2 glucose tolerance
with high-fat high-sucrose diet 		Area under curve. DO population both 4-26wks 2018
Attie2 hormone quantification
with high-fat high-sucrose diet 		Plasma insulin, adiponectin, leptin. Ex vivo insulin secretion. DO population both 4-26wks 2018
Attie2 intake monitoring
with high-fat high-sucrose diet 		Food intake. Weekly. DO population both 4-26wks 2018
Attie2 lipid profile
with high-fat high-sucrose diet 		Triglyceride. DO population both 4-26wks 2018
Attie2 metabolic panel
with high-fat high-sucrose diet 		Glucose, HOMA-IR, HOMA-B. DO population both 4-26wks 2018
Attie2 microscopy
with high-fat high-sucrose diet 		Number of islets harvested. DO population both 4-26wks 2018
Attie2 organ weights
with high-fat high-sucrose diet 		Heart, liver, gonadal fat pads. DO population both 4-26wks 2018
Chesler4 body weight Body weight DO population w/par   (9) both 12-16wks 2013
Chesler4 light-dark box Anxiety, avoidance behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 nociception assay Hot plate. DO population w/par   (9) both 12-16wks 2013
Chesler4 open field test Locomotor activity, exploratory, anxiety-related behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 tail suspension test Frequency climbing, time immobile, latency immobile. 5 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 visual cliff Anxiety, avoidance behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Dickson2 hole board test
with cocaine 		Exploratory behavior. 10 min test. DO population both 12-16wks 2015
Dickson2 monitoring system
with cocaine 		Novelty preference test (preference for novel side vs. familiar side). 10 min test. DO population both 12-16wks 2015
Dickson2 open field test
with cocaine 		Locomotor activity and exploratory behavior. 20 min test. DO population both 12-16wks 2015
Dickson2 operant conditioning chamber
with cocaine 		Intravenous self-administration of cocaine via activation of levers. DO population both 12-16wks 2015
Gatti2 study archive Whole blood neutrophil count and white cell count. DO population both 10-12wks 2014
Hallgrimsson1 body weight Body weight DO population both 8-60 wks 2020
Hallgrimsson1 bone dimensions 3D, craniofacial landmark coordinates based on centroid. DO population both 8-60 wks 2020
Recla1 study archive Hot plate nociception. DO population both 13-17wks 2013
Recla2 nociception assay Formalin injection. DO population both 13-17wks 2019
Shorter8 body weight Body weight DO population m 12-15wks 2020
Shorter8 histopathology Male reproductive histopathology. Percent normal, abnormal sperm. DO population m 12-15wks 2020
Shorter8 microscopy Sperm motility DO population m 12-15wks 2020
Shorter8 organ weights Male reproductive organ weights. Testes, seminal vesicles, epididymis + vas deferens. DO population m 12-15wks 2020
Shorter8 sperm count Sperm count. Hemocytometer. DO population m 12-15wks 2020
Xenakis2 body weight
with arsenic 		Baseline, then after iAs exposure for 26 wks DO population m 4-34 wks 2022
Xenakis2 hormone quantification
with arsenic 		Blood insulin following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure DO population m 4-34 wks 2022
Xenakis2 intake monitoring
with arsenic 		Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure DO population m 4-34 wks 2022
Xenakis2 metabolic panel
with arsenic 		Blood glucose following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure DO population m 4-34 wks 2022
Xenakis2 metabolite quantification
with arsenic 		iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) DO population m 4-34 wks 2022
Xenakis2 MRI
with arsenic 		Fat and lean tissue mass at baseline, and 12 and 24 wks after iAs exposure DO population m 4-34 wks 2022
Xenakis2 urinalysis
with arsenic 		Urine volume at baseline, and 12 and 24 wks after iAs exposure DO population m 4-34 wks 2022